[HTML][HTML] Thrombosis in vasculitis: from pathogenesis to treatment
In recent years, the relationship between inflammation and thrombosis has been deeply
investigated and it is now clear that immune and coagulation systems are functionally …
investigated and it is now clear that immune and coagulation systems are functionally …
[HTML][HTML] Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside
D Squatrito, G Emmi, E Silvestri, L Ciucciarelli… - Autoimmunity …, 2014 - Springer
Systemic lupus erythematosus (SLE) is considered an autoimmune disease with multiorgan
involvement. Many advances have been made during the last decade regarding …
involvement. Many advances have been made during the last decade regarding …
Behçet's syndrome pathophysiology and potential therapeutic targets
G Emmi, E Silvestri, D Squatrito, MM D'Elios… - Internal and emergency …, 2014 - Springer
Behçet syndrome is a systemic inflammatory disorder characterized by multiorgan
involvement such as oral and genital ulcers, uveitis, skin lesions as well as by less frequent …
involvement such as oral and genital ulcers, uveitis, skin lesions as well as by less frequent …
Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet disease
Background—Behçet disease (BD) is a systemic vasculitis with a broad range of organ
involvement, characterized by a multisystemic, immune-inflammatory disorder involving …
involvement, characterized by a multisystemic, immune-inflammatory disorder involving …
[HTML][HTML] Off-label use of rituximab for systemic lupus erythematosus in Europe
M Rydén-Aulin, D Boumpas, I Bultink… - Lupus science & …, 2016 - lupus.bmj.com
Objectives Rituximab (RTX) is a biological treatment used off-label in patients with systemic
lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in …
lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in …
[HTML][HTML] Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-α in early phases of the disease
Background: Gastrointestinal involvement is one of the most serious in Behçet disease,
potentially leading to severe complications. Aim of this study was to investigate at mucosal …
potentially leading to severe complications. Aim of this study was to investigate at mucosal …
[HTML][HTML] An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions
G Emmi, E Silvestri, D Squatrito, L Ciucciarelli… - The scientific world …, 2014 - hindawi.com
The antiphospholipid antibody syndrome is a systemic, acquired, immune-mediated
disorder characterized by episodes of venous, arterial, or microcirculation thrombosis and/or …
disorder characterized by episodes of venous, arterial, or microcirculation thrombosis and/or …
Microparticles: bridging the gap between autoimmunity and thrombosis
E Niccolai, G Emmi, D Squatrito… - … in thrombosis and …, 2015 - thieme-connect.com
Microparticles (MPs) are irregularly shaped small vesicles of heterogeneous size released
from the plasma membrane in a tightly controlled process, after different stimuli. MPs have …
from the plasma membrane in a tightly controlled process, after different stimuli. MPs have …
Thrombosis in autoimmune diseases: a role for immunosuppressive treatments?
E Silvestri, A Scalera, G Emmi… - … in Thrombosis and …, 2016 - thieme-connect.com
Autoimmune diseases are not infrequently associated with arterial or venous thrombotic
events. Chronic inflammation and immune system impairment are considered the main …
events. Chronic inflammation and immune system impairment are considered the main …
Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Behçet׳ s disease
G Emmi, E Silvestri, D Squatrito… - … in arthritis and …, 2016 - pubmed.ncbi.nlm.nih.gov
Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Behçet׳s
disease Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory …
disease Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory …